Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a $140 price target.
August 01, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Jazz Pharmaceuticals and maintained a $140 price target.
The reiteration of an Overweight rating and a maintained price target of $140 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100